Trump’s Most Favored Nation Drug Pricing Has Bold Aims, But Limited Impact

The Trump administration is pushing a most-favored-nation drug pricing plan through private deals with 17 drugmakers, a Medicaid rebate model called GENEROUS, and a TrumpRx cash-pay platform.

It also announced lower GLP-1 prices with Eli Lilly and Novo Nordisk, but the article questions how much these moves will actually reduce costs.

The expected savings may be limited, hard to verify, and potentially temporary if agreements expire or do not change list prices.

The policy could still lower some U.S. drug spending, especially in Medicaid, but its broader impact remains uncertain.